AR Names New Distributors in Europe, Expanding Its Global Distribution Network

SOUDERTON, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) — AR, a worldwide leader in microwave technology, is pleased to announce it has signed distributor agreements with Elhyte, Melcom, and Tactron, expanding AR’s global distribution footprint in Europe.

All three distributors specialize in the sales and marketing of RF/Microwave instruments.

Effective October 1, 2023:

  • Elhyte is appointed as AR’s distributor in France,
  • Melcom is appointed as AR’s distributor in the United Kingdom and Ireland,
  • Tactron is appointed as AR’s distributor in Germany and Austria.

Jerry Miller, AR Sales Vice President, states, “We are confident that these relationships will provide our customers with timely, valued solutions.”

AR will continue to provide company-owned maintenance and repair service out of Paris, France.

About AR
For over 50 years, AR has played a significant role in the success of the aerospace, defense, automotive, medical, commercial, and telecom industries. The RF/Microwave Instrumentation division of AR provides Total RF Test Solutions by offering customers RF test instrumentation, RF test systems, and EMC test software. In addition to the complete array of product solutions, AR brings world-class customer service and application support; from calibration and regular maintenance to troubleshooting and repairs, you can depend on AR’s service and support teams.

For more information, contact AR RF/Microwave Instrumentation, 160 Schoolhouse Rd., Souderton, PA 18964 by phone 215-723-8181 or

About Elhyte
For over 40 years, Elhyte has developed the RF/Microwave, millimeter wave and submillimeter wave components, test equipment and subsystems business in France by selecting very innovative partners and bringing competitive solutions to our customers. ELHYTE is recognized for its excellent customer service.

For more information, please contact ELHYTE, 8-10 Rue du Bois Sauvage, 91000 Evry, France by phone +33 (0) 1 71 63 14 30 or

About Melcom
Since 1995, Melcom’s objective has been to provide the very best technical and commercial support to our customers, by offering an innovative, high quality and high performance product portfolio to the RF, Microwave and millimeter wave industry. Our extensive experience over the years has seen successful delivery of major programs across the Defense, Space, Test & Measurement, Commercial Aerospace and Commercial Communications market sectors.

For more information, please contact Melcom Electronics Ltd, Quantum House, 59-61 Guildford Street, Chertsey, Surrey, KT16 9AX, United Kingdom by phone +44(0)1932565544 or

About Tactron
For around 40 years, Tactron has been the consultant and specialist for RF and Microwave components, measurement instruments and systems for applications in the automotive, military, healthcare, test & measurement and satellite communication markets. We have proudly provided high quality services and products with a proven track record since 1984.

For more information, contact Tactron Elektronik GmbH & Co KG, Lochhamer Schlag 5, 82166 Graefelfing Germany by phone: +49 89895569 0 or

CONTACT: Jerry Miller, VP Sales

GlobeNewswire Distribution ID 8925565

Gorilla Announces $25 Million Registered Direct Offering of Convertible Preferred Stock

LONDON, Sept. 20, 2023 (GLOBE NEWSWIRE) — Gorilla Technology Group Inc. (“Gorilla”) (NASDAQ: GRRR), a global provider of AI-based edge video analytics, IoT technologies, and cybersecurity, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 25,000 Series A convertible preference shares (the “Series A preference shares”) at a purchase price of $1,000 per share pursuant to a registered direct offering, resulting in total gross proceeds of approximately $25 million before deducting placement agent commissions and other estimated offering expenses. Each Series A preference share is convertible into ordinary shares of Gorilla at a conversion price of $1.25 per share. Along with the Series A preference shares, Gorilla further agreed to issue to the investors Series A ordinary share purchase warrants (the “Series A warrants”) to purchase up to an aggregate of 20,000,000 ordinary shares of Gorilla. The Series A warrants will have an exercise price of $1.50, will be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about September 22, 2023, subject to the satisfaction of customary closing conditions.

Cantor Fitzgerald & Co. and A.G.P./Alliance Global Partners are acting as co-lead placement agents for the offering.

The gross proceeds to Gorilla from this offering are expected to be approximately $25 million, before deducting the placement agents’ fees and other offering expenses. Gorilla intends to use the net proceeds from the offering for working capital needs.

The securities described above are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-274053) that was filed with the Securities and Exchange Commission (the “SEC”) on August 17, 2023 and declared effective by the SEC on August 29, 2023. The offering is being made by means of a prospectus, including a prospectus supplement, that form part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at or by contacting Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022, or by e-mail at, or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Contact:
Jeff Fox
The Blueshirt Group for Gorilla
+1 (415) 828-8298

Investor Relations Contacts:
Gary Dvorchak
The Blueshirt Group for Gorilla
+1 (323) 240-5796

Scott McCabe
The Blueshirt Group for Gorilla
+1 (917) 434-3275

GlobeNewswire Distribution ID 8925337

WilsonHCG named No. 1 global RPO provider in HRO Today’s 2023 RPO Baker’s Dozen List

TAMPA, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) — WilsonHCG has been recognized as the No. 1 Recruitment Process Outsourcing (RPO) provider in HRO Today’s 2023 Baker’s Dozen List.

The longest-standing customer satisfaction survey in the RPO industry, HRO Today’s Baker’s Dozen List is designed to highlight the world’s top RPO providers and lends transparency into the RPO partnerships that are most impactful. Providers are rated on a range of factors including breadth of solutions, quality of service and size of deal.

“It’s an honor to be ranked No. 1 in the Baker’s Dozen List,” said John Wilson, CEO at WilsonHCG. “This recognition means so much to us as a business because it’s solely driven by client feedback. It really is a testament to the commitment and care that our people place in our client relationships. I want to say a huge thank you to the team and can’t wait to build on this success as we continue to add even more value to our client partnerships.”

“Since WilsonHCG’s first placement on the HRO Today Baker’s Dozen as a challenger brand, it has focused on great customer service and innovative approaches to recruitment process outsourcing and workforce solutions. It has transitioned from its early days as a challenger to a large and market dominating leader which is helping redefine what success should look like for clients of these service offerings. Remarkably, WilsonHCG’s service orientation has continued to improve as it has grown to one of the largest and most successful companies in the space and we congratulate it and its leadership team on ranking as the top provider on the HRO Today RPO Baker’s Dozen,” said Elliot Clark, CEO of HRO Today.

Visit the HRO Today website here to find more information about the Baker’s Dozen List.

About WilsonHCG
WilsonHCG is an award-winning, global leader in total talent solutions. Operating as a strategic partner, it helps some of the world’s most admired brands build comprehensive talent functions. With a global presence spanning more than 65 countries and six continents, WilsonHCG provides a full suite of configurable talent services including recruitment process outsourcing (RPO), executive search, contingent talent solutions and talent consulting.

TALENT.™ It’s more than a solution, it’s who we are.

Media contact

+44 7889901517


GlobeNewswire Distribution ID 8925480

Acino significantly expands presence and capabilities in Latin America through acquisition of M8 Pharmaceuticals

Over 300 M8 employees, product portfolio and pipeline to enhance Acino’s footprint and strategic position in key Latin American markets.

Zurich, Switzerland, Sept. 20, 2023 (GLOBE NEWSWIRE) — Acino, a Swiss pharmaceutical company headquartered in Zurich, today announced that it has entered into an agreement to acquire M8 Pharmaceuticals (M8), a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.

Through this acquisition, Acino will enter the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region, providing a more powerful and comprehensive offering for healthcare professionals and patients. The acquisition will complement Acino’s existing Latin American division, which is based in Panama and operates across eight countries in Central America, the Caribbean, and Ecuador, delivering high-quality medicines to improve people’s health in this key region.

M8, a Montreux Growth Partners portfolio company, has a highly successful record of signing exclusive licensing agreements with large pharmaceutical and biotech companies for the rights to market and commercialize products in Latin America. M8 brings a portfolio of well-known proven brands and innovative products, a best-in-class deal-making platform and an outstanding reputation among its partners. Moreover, it has built a large pipeline across a broad range of key therapeutic areas, including CNS, cardiometabolism, respiratory, gastroenterology, oncology and hematology, and rare diseases.

Andrew Bird, Interim CEO at Acino commented: “This is a transformative deal for Acino, significantly expanding our presence in Latin America and delivering against our overall strategy and stated intention to increase patient’s access to high-quality pharmaceuticals and diversify our footprint in key high-growth markets. We see M8 and Acino as highly complementary offerings, and we are confident that we can use this acquisition as a catalyst to further increase value and accelerate growth for Acino in this key region.”

Joel Barlan, CEO at M8 commented: “This agreement will provide M8 with considerable additional resources, expertise, and access to a much wider geographic footprint, which will further accelerate our growth. We look forward to leveraging the skills and capabilities of both teams to grow the combined business and continue to bring proven and innovative treatments to patients and caregivers throughout Latin America and other emerging markets.”

Dan Turner, Managing Director at Montreux Growth Partners commented: “We could not be more pleased with what M8 has achieved during our ownership. We first invested in the early stages of its development. We were able to bring on board a world-class management team, who have focused the company on patient critical therapeutic areas, with a product portfolio that now includes over 30 leading brands from major pharmaceutical companies around the world. The company has delivered tremendous growth and profitability, while also doing much good for the lives of patients. Acino is the perfect acquirer to continue that history of success”.

The transaction is subject to customary closing conditions, including antitrust clearance, and is expected to be completed by the end of 2023. Banco J.P. Morgan S.A. is acting as exclusive financial advisor, Goodwin LLP as exclusive legal advisor, and PWC as exclusive accounting and tax advisor to Acino. Stifel, Cooley LLP and Credit Suisse, a UBS Group Company acted as advisors to M8.

About AcinoAcino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. Acino is part of ADQ, an Abu Dhabi based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.

About M8 Pharmaceuticals

M8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in Latin America: Brazil and Mexico. We aim to become the preferred pharmaceutical partner for the licensing of high-value innovative and proven therapies across our main therapeutic areas CNS, respiratory, cardiometabolic, immunology, gastroenterology, onco-hematology, and rare diseases. Our mission is to provide the people of Latin America with access to the proven and innovative medicines they need to transform their lives.

About Montreux Growth Partners

Founded in 1993, Montreux Growth Partners has a long history of investing growth capital into category-leading companies that are advancing healthcare and financial technology. It focuses on commercial stage companies which have highly differentiated products, technologies, and services. It is an active and collaborative investor, working closely with the management teams at its portfolio companies.


Larisa Bernstein, Global Head of Communications

M8 Pharmaceuticals
Joel Barlan, Chief Executive Officer
+52 (55) 4431 2933

Rafael Ferrer, Vice President of Corporate Development & Strategy
+1 (305) 299 6998

GlobeNewswire Distribution ID 8925525

VistaJet announces new partnership with maverick Burgundy winemaker Olivier Bernstein

VistaJet Wine Program

Cellar-to-cellar transportation

  • The most sough-after wine in the world;
  • A handpicked selection of Grand Cru wines for VistaJet Members to enjoy on board the Global 7500 fleet;
  • A limited edition seven-bottle case of specially selected Grand Cru wines available directly to VistaJet Members;
  • Demonstrating passion and vision once again, VistaJet launches the first of its kind cellar-to-cellar global wine transportation service to guarantee the quality and authenticity of Olivier Bernstein wines for collectors anywhere, anytime.

London, September 20th, 2023: VistaJet, the first and only global business aviation company, expands its iconic wine program with an exclusive partnership with Olivier Bernstein to offer wine drinkers and collectors the opportunity to savor and connect with one of Burgundy’s finest winemakers — both in-flight on board the game-changing Global 7500 aircraft and at destination. The partnership is also celebrated with the creation of a limited edition seven-bottle case of a specially selected assortment of Grand Cru wines, which will be available for Members to purchase and deliver to their cellar directly from Bernstein’s cellar in Beaune, France.

This pioneering move came to fruition after a conversation between VistaJet Founder and Chairman Thomas Flohr and Bernstein, about how best to maintain the integrity of fine wines.

We have worked with experts to understand how taste and smell are affected by the atmosphere in a pressurized cabin and found that nasal sensors’ reception of aromas are limited owing to the lower air pressure that comes with a lower humidity. In particular, fruit flavors become diminished, while bitterness and spiciness are largely unaffected. These insights allow us to carefully select wines that will give the best flavor and fullness at altitude.” — Thomas Flohr, VistaJet’s Founder and Chairman.

Burgundy wines are fragile, complex and can be quite difficult to understand. They can lose their magic and sensuality if they are not correctly stored or delivered. Sourcing directly from the growers’ cellars and having them delivered directly is, to me, the ultimate guarantee of quality.” — Olivier Bernstein.

VistaJet x Olivier Bernstein

Handpicked selection of Grand Cru wines for VistaJet Members

Offering this additional and exclusive service to its Members is an example of VistaJet’s commitment to providing a seamless, dedicated service. VistaJet’s global infrastructure and network make it possible to offer this creative service to its clients in any part of the world.

For our Members, who are wine collectors and connoisseurs, this service guarantees safe transportation of their precious wine, with no change of hands in transit. We fly globally, so we can offer ultimate convenience and safety anywhere in the world.Matteo Atti, Chief Marketing Officer, VistaJet.

Wine in the sky

Enjoy onboard the Global 7500 fleet

The partnership brings together two visionary brands that are pioneers in their industries. In only 20 years, both Bernstein’s wines and VistaJet have grown quickly to global acclaim. The combination of passion and creativity with business sets VistaJet apart in the private aviation industry. Initiatives such as VistaJet’s jet-to-cellar demonstrate the company’s commitment to offering not just efficient and reliable private journeys, but the most considered and private travel services.

VistaJet has created the first global program to offer the best possible wine experience in the sky and catering to Members collecting, discovering and developing a deeper knowledge of wine from every region in the world. To further enhance the onboard tasting, VistaJet Cabin Hosts are also trained by the Wine & Spirit Education Trust to Level 2.

VistaJet’s onboard Signature Wine List includes wines sourced from some of the world’s most iconic vineyards considering the effects of flying on taste. The list features classics such as Ruinart Champagnes, Pessac Léognan and the Gaja Rossj Bass Chardonnay, as well as Napa’s Newton Winery Single Vineyard Chardonnay ‘The Bay’ 2018 and Newton Winery Single Vineyard Cabernet Sauvignon Spring Mountain 2018.

To complete the journey, VistaJet Private World connects its Members to the most incredible Chateaux, enhancing tastings with visits and personal introductions to the most incredible wine creators.

To discover more about how to enjoy wine when traveling, The Wine In The Sky Questionnaire is a compendium of suggestions for tasting, serving and transporting wine on travels around the world, and includes musings from popular oenophiles including Sofia Coppola, Andrea Bocelli, Jeannie Cho Lee and Daniel Boulud. Published in collaboration with Assouline, the book advises how to select the most appropriate wines accounting for the effects of flying on our senses.


VistaJet |

About VistaJet  
VistaJet is the first and only global business aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world.
Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.
VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.
More VistaJet information and news at

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet US Inc. is an Air Charter Broker that does not operate aircraft. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S.

Attachments –

GlobeNewswire Distribution ID 1000840316

Malaysia Showcases Its World-Class Healthcare Offerings at Oman Health 2023

Malaysia Healthcare offers exclusive packages from leading private hospitals in the areas of fertility, oncology, orthopaedics, and premium wellness.

Oman Healthcare-1

(From Left) Datuk Dr Azmin Kass, Consultant Neurosurgeon KPJ Damansara Specialist Hospital 2; Farizal B Jaafar, Acting CEO of MHTC; Ms Hafsah Mukhtar, Senior General Manager KPJ Healthcare Berhad; Ms Amal Mahfoudh Hezam, Senior Corporate Marketing Executive KPJ Healthcare Berhad; Dr Nur Adila Anuar, Consultant Clinical Haematology KPJ Ampang Puteri Specialist; HE Shaiful Anuar Mohammad, Ambassador Of Malaysia to Oman, at Oman Health Exhibition and Conference 2023.

MUSCAT, Oman, Sept. 20, 2023 (GLOBE NEWSWIRE) — Malaysia Healthcare is showcasing its world-class healthcare offerings to Omanis, at the annual Oman Health Exhibition and Conference (OHEC), held at the Oman Convention & Exhibition Centre in Muscat. Malaysia Healthcare Travel Council (MHTC), an agency under the Ministry of Health (MOH) Malaysia entrusted to facilitate and promote Malaysia’s healthcare travel industry, together with several leading private hospitals in the country are present at the Malaysian Pavillion, under the brand ‘Malaysia Healthcare’ from 18th to 20th September 2023 at booth No. 5500.

Featuring medical experts and specialist consultants in fertility, oncology, orthopaedics, and rehabilitation, from award-winning private hospitals in Malaysia such as Alpha IVF & Women’s Specialists, KPJ Healthcare Berhad, and Sunway Medical Centre, based in greater Kuala Lumpur, Malaysia Healthcare invites interested individuals in seeking treatments abroad to explore the exclusive healthcare packages, as well as potential partners to network with its representatives at the Malaysia Healthcare Pavillion.

Oman Healthcare-2

Farizal B Jaafar, Acting CEO of MHTC, presenting the welcoming remarks on behalf of Dr. Zaliha Mustafa, Honourable Minister of Health, Malaysia at Oman Health Exhibition and Conference 2023.

The OHEC provides a platform for valuable exchange on medical knowledge, expertise, technology, and best practices among global healthcare players. Representing the Honourable Minister of Health Malaysia, Dr. Zaliha Mustafa as one of the key speakers during the event, the Acting Chief Executive Officer of MHTC, Farizal B. Jaafar had the opportunity to share key highlights on Malaysia’s approach to healthcare reforms and advancements within the country’s healthcare sector outlined in its recently launched Health White Paper.

“With a keen focus on the well-being of its people, the Sultanate of Oman has taken numerous efforts through Oman’s Health Vision 2050 to develop a strong healthcare ecosystem that is sustainable, inclusive, and highly responsive to the needs of the community. In this perspective, Oman and Malaysia share an aligned aspiration for healthcare reform. Under the Health White Paper, Malaysia aspires to nurture a nation of well-being by creating a healthcare system that is fair, easily accessible, and centered around the people’s needs. This commitment reaches far beyond our borders and extends across all subsectors. Through healthcare travel, we aspire to provide the same quality of care to the broader global community,” said Farizal B. Jaafar, Acting Chief Executive Officer of MHTC.

Oman Healthcare-3

Acting CEO of MHTC, Farizal B Jaafar together with Sayyid Khalid bin Hamad Al Busaidi, Chairman of SABCO group Oman, and other guests at the Malaysia Pavilion.

“MHTC has been successful in establishing public-private partnerships in various markets, fostering relations to facilitate patients to obtain quality treatments in Malaysia. Building upon the success of these partnerships, we look forward to building relationships with strategic Middle Eastern industry players to expand the reach of our quality and affordable healthcare to the Middle Easterners, especially the Omanis, addressing the trend among Omanis seeking healthcare treatments abroad,” added Farizal.

In addition to government-to-government relations, MHTC has also collaborated with globally recognised organisations to drive medical and service excellence, as well as elevate international branding. These include the renowned Mayo Clinic, Healthcare Information and Management Systems Society (HIMMS), international accreditation bodies like Joint Commission International (JCI) as well as global airlines, financial and insurance service providers, technology enablers, and more.

Healthcare travel in Malaysia is a well-developed industry, serving as a key export service for the country. Rigorously regulated by the Ministry of Health Malaysia, the industry is one of the few countries in the region to receive strong government backing to ensure impeccable standards of quality, safety, and ethics in Malaysian healthcare services.

In addition, Malaysia Healthcare is highly competitive and affordable, providing cutting-edge treatments that are on par with countries such as the USA, United Kingdom, Europe, and Japan, at a very reasonable cost. This cost efficiency is also an attribute of the strict regulations on pricing outlined by the Ministry of Health Malaysia, to ensure that healthcare in Malaysia remains accessible to everyone who needs it.

“We are excited to be a part of the OHEC, and look forward to exploring innovative opportunities, showcasing the latest technologies, services, and facilities, and leveraging investment opportunities. Malaysia Healthcare is here to provide some of the advanced and cutting-edge facilities to all Omanis and healthcare travellers from this region to be treated in Malaysia, providing exceptional care within a safe and trusted destination for their peace of mind,” said Farizal.

There are currently more than 200 private hospitals in Malaysia, where only the most well-equipped and service-ready facilities are approved and registered to be participating healthcare travel providers. Most doctors and healthcare professionals in Malaysia received their training from internationally acclaimed institutions in Malaysia, USA, United Kingdom, Australia and Europe, and Malaysian private hospitals possess accreditation from reputable institutions, such as the Joint Commission International (JCI), Reproductive Technology Accreditation Committee (RTAC), Australian Council on Healthcare Standards (ACHS) and Malaysian Society for Quality in Health (MSQH).

Notably, several of Malaysia’s private hospitals have earned prestigious rankings, including recognition as top hospitals for various treatments, such as cardiology, endocrinology, neurology, oncology, orthopaedics, and paediatrics in the esteemed Newsweek’s Best Specialised Hospitals Asia Pacific 2023 survey. Additionally, Malaysia has been recently listed as the top destination for retirement living in Asia by Nasdaq and International Living Magazine.

For comprehensive information on Malaysia Healthcare and its services, including healthcare travel, visit Stay updated with Malaysia Healthcare by following our social media accounts on Facebook at and on LinkedIn through the Malaysia Healthcare Travel Council.

For media enquiries:

Tutie Ismail
Vice President
Malaysia Healthcare Travel Council
Chandrika Bhaskaran
Senior Manager
Public Relations & Content Communications
Malaysia Healthcare Travel Council

The Malaysia Healthcare Travel Council (MHTC) is a government agency under the Ministry of Health Malaysia that has been entrusted with the responsibility of curating the country’s healthcare travel scene, making it a key export service industry. Founded in 2009, MHTC works to streamline industry players and service providers in facilitating and growing Malaysia’s healthcare travel industry under the brand “Malaysia Healthcare” with the intended goal of making Malaysia the leading global healthcare destination. MHTC works closely with over 90 private healthcare facilities in Malaysia, who are registered members of MHTC.

Photos accompanying this announcement are available at

GlobeNewswire Distribution ID 8925315